Evidence map›Paper›PMID 38470384›Full record

ArticleJAMA2024

Adolescent Δ8-THC and Marijuana Use in the US.

Alyssa F Harlow, Richard A Miech, Adam M Leventhal

Open access · greenAbstract readComparative Study
In one paragraph

Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
21.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, Update 2018-2023: Current Status, Best Practices, and Opportunities for Advancing the Science.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
    Pooled it
  2. Trial
  3. Article
  4. In Vitro Metabolism of ΔDrug testing and analysis · 2026
    Article
  5. Article
  6. Article
  7. Correlates of Derived Cannabis Product Awareness, Knowledge, Use, and Use Intentions Among Young Adults.Health education & behavior : the official publication of the Society for Public Health Education · 2026
    Article
  8. The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.Current topics in behavioral neurosciences · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Severe Outcomes in Suspected Pediatric Delta-8-THC Exposures.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alyssa F HarlowDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles.
Richard A MiechInstitute for Social Research, University of Michigan, Ann Arbor, Michigan.
Adam M LeventhalDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles.
University of Southern California · USUniversity of Michigan–Ann Arbor · US

Funding

Monitoring the Future: Drug Use & Lifestyles of American Youth (Supp1: Nicotine Pouch and E-cigarette Use Among US Adolescents: National Estimates of Brand Use and Flavor Preferences)R01DA001411 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Richard A Miech · 1985 to 2026
$144.9M
Tobacco Use Treatment Research for Vulnerable PopulationsK24DA048160 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Adam Matthew Leventhal · 2019 to 2026
$1.4M
The Tobacco and Cannabis Retail Environment, Neighborhood Disadvantage, and Adolescent VapingK01DA058084 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Alyssa Fitzpatrick Harlow · 2023 to 2026
$752k
NIDA NIH HHS K01 DA058084NIDA NIH HHS K24 DA048160NIDA NIH HHS R01 DA001411
6 · The paper itself

Abstract

Importance: Gummies, flavored vaping devices, and other cannabis products containing psychoactive hemp-derived Δ8-tetrahydrocannabinol (THC) are increasingly marketed in the US with claims of being federally legal and comparable to marijuana. National data on prevalence and correlates of Δ8-THC use and comparisons to marijuana use among adolescents in the US are lacking. Objective: To estimate the self-reported prevalence of and sociodemographic and policy factors associated with Δ8-THC and marijuana use among US adolescents in the past 12 months. Design, Setting, and Participants: This nationally representative cross-sectional analysis included a randomly selected subset of 12th-grade students in 27 US states who participated in the Monitoring the Future Study in-school survey during February to June 2023. Exposures: Self-reported sex, race, ethnicity, and parental education; census region; state-level adult-use (ie, recreational) marijuana legalization (yes vs no); and state-level Δ8-THC policies (regulated vs not regulated). Main Outcomes and Measures: The primary outcome was self-reported Δ8-THC and marijuana use in the past 12 months (any vs no use and number of occasions used). Results: In the sample of 2186 12th-grade students (mean age, 17.7 years; 1054 [48.9% weighted] were female; 232 [11.1%] were Black, 411 [23.5%] were Hispanic, 1113 [46.1%] were White, and 328 [14.2%] were multiracial), prevalence of self-reported use in the past 12 months was 11.4% (95% CI, 8.6%-14.2%) for Δ8-THC and 30.4% (95% CI, 26.5%-34.4%) for marijuana. Of those 295 participants reporting Δ8-THC use, 35.4% used it at least 10 times in the past 12 months. Prevalence of Δ8-THC use was lower in Western vs Southern census regions (5.0% vs 14.3%; risk difference [RD], -9.4% [95% CI, -15.2% to -3.5%]; adjusted risk ratio [aRR], 0.35 [95% CI, 0.16-0.77]), states in which Δ8-THC was regulated vs not regulated (5.7% vs 14.4%; RD, -8.6% [95% CI, -12.9% to -4.4%]; aRR, 0.42 [95% CI, 0.23-0.74]), and states with vs without legal adult-use marijuana (8.0% vs 14.0%; RD, -6.0% [95% CI, -10.8% to -1.2%]; aRR, 0.56 [95% CI, 0.35-0.91]). Use in the past 12 months was lower among Hispanic than White participants for Δ8-THC (7.3% vs 14.4%; RD, -7.2% [95% CI, -12.2% to -2.1%]; aRR, 0.54 [95% CI, 0.34-0.87]) and marijuana (24.5% vs 33.0%; RD, -8.5% [95% CI, -14.9% to -2.1%]; aRR, 0.74 [95% CI, 0.59-0.94]). Δ8-THC and marijuana use prevalence did not differ by sex or parental education. Conclusions and Relevance: Δ8-THC use prevalence is appreciable among US adolescents and is higher in states without marijuana legalization or existing Δ8-THC regulations. Prioritizing surveillance, policy, and public health efforts addressing adolescent Δ8-THC use may be warranted.

Indexed as

DronabinolHallucinogensMarijuana UseSubstance-Related DisordersAdolescentAdultCannabisCross-Sectional StudiesFemaleHumansMaleMarijuana SmokingPrevalenceRacial GroupsSelf ReportStudentsdelta-8-tetrahydrocannabinolDronabinolHallucinogens

Identifiers

PMID38470384
PMCPMC10933714
OpenAlexW4392702224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.